Jeffrey McCullough - Transfusion Medicine

11 11. Mast AE, Bialkowski W, Bryant BJ, et al. A randomized, blinded, placebo‐controlled trial of education and iron supplementation for mitigation of iron deficiency in regular blood donors. Transfusion 2016; 56:1588–1597.

12 12. Schmidt PJ. Blood donation by the healthy elderly. Transfusion 1991; 31:681–683.

13 13. Mast AE. Putting donor health first in strategies to mitigate donor iron deficiency. Transfusion 2017; 57(3):495–498.

14 14. Sanchez AM, Schreiber GB, Glynn SA, et al. Blood‐donor perceptions of health history screening with a computer‐assisted self‐administered interview. Transfusion 2003; 43:165–167.

15 15. Steele WR, Hewitt EH, Kaldun AM, et al. Donors deferred for self‐reported Chagas disease history: does it reduce risk? Transfusion 2014; 54(8):2092–2097.

16 16. O’Brien SF, Chiavetta JA, Goldman M, et al. Predictive ability of sequential surveys in determining donor loss from increasingly stringent variant Creutzfeldt–Jakob disease deferral policies. Transfusion 2006; 46:461–468.

17 17. O’Brien SF, Fan W, Yi QL, et al. Variant Creutzfeldt‐Jakob disease deferral in Canada: impact of stop dates. Blood Transfus 2018; 16:26–31.

18 18. Murphy EL, Connor JD, McEvoy P, et al. Estimating blood donor loss due to the variant CJD travel deferral. Transfusion 2004; 44:645–650.

19 19. Spencer B, Steele W, Custer B, et al. Risk for malaria in United States donors deferred for travel to malaria‐endemic areas. Transfusion 2009; 49:2335–2345.

20 20. US Food and Drug Administration. Blood Products Advisory Committee Meeting FDA White Oak Campus, Silver Spring, MD, March 20‐21, 2019 [Internet]. Available at: https://www.fda.gov/media/120953/download

21 21. Custer B, Sheon N, Siedle‐Khan B, et al. Blood donor deferral for men who have sex with men: the Blood Donation Rules Opinion Study (Blood DROPS). Transfusion 2015; 55(12):2826–2834.

22 22. Davison KL, Gregoire Y, Germain M, et al. Changing the deferral for men who have sex with men—an improved model to estimate HIV residual risk. Vox Sang 2019; 114(7):666–674.

23 23. O’Brien SF, Grégoire Y, Pillonel J, et al. HIV residual risk in Canada under a three‐month deferral for men who have sex with men. Vox Sang 2020; 115(2):133–139.

24 24. Wang B, Higgins MJ, Kleinman S, et al. Comparison of demographic and donation profiles and transfusion‐transmissible disease markers and risk rates in previously transfused and nontransfused blood donors. Transfusion 2004; 44:1243–1251.

25 25. Busch MP, Young MJ, Samson SJ, et al. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV‐1 antibody screening. Transfusion 1991; 31:4–11.

26 26. Lefrere JJ, Elghouzzi MH, Salpetrier J, et al. Interviews of individuals diagnosed as anti‐human immunodeficiency virus‐positive through the screening of blood donations in the Paris area from 1991 to 1994: reflections on the selection of blood donors. Transfusion 1996; 36:124–127.

27 27. Doll LS, Petersen LR, White CR. Human immunodeficiency virus type 1‐infected blood donors: behavioral characteristics and reasons for donation. Transfusion 1991; 31:704–709.

28 28. McDonnell SM, Grindon AJ, Preston BL, et al. A survey of phlebotomy among persons with hemochromatosis. Transfusion 1999; 39:651–656.

29 29. Hoad V, Bentley P, Bell B, et al. The infectious disease blood safety risk of Australian hemochromatosis donations. Transfusion 2016; 56:2934–2940.

30 30. Leitman SF, Browning JN, Yau YY, et al. Hemochromatosis subjects as allogeneic blood donors: a prospective study. Transfusion 2003; 43:1538–1544.

31 31. West KA, Eder AF. Accepting hereditary hemochromatosis blood donors: ask not why, ask why not. Transfusion 2016; 56:2907–2909.

32 32. Lewis SM, Emmanuel J. Validity of the haemoglobin colour scale in blood donor screening. Vox Sang 2001; 80:28–33.

33 33. De Clippel D, Van Heddegem L, Vandewalle G, et al. Hemoglobin screening in blood donors: a prospective study assessing the value of an invasive and a noninvasive point‐of‐care device for donor safety. Transfusion 2017; 57(4):938–945.

34 34. Wood EM, Kim DM, Miller JP. Accuracy of predonation Hct sampling affects donor safety, eligibility, and deferral rates. Transfusion 2001; 41:353–359.

35 35. Lau P, Hansen M, Sererat M. Influence of climate on donor deferrals. Transfusion 1989; 28:559–562.

36 36. Cable RG, Glynn SA, Kiss JE, et al. Iron deficiency in blood donors: analysis of enrollment data from the REDS‐II donor iron status evaluation (RISE) study. Transfusion 2011; 51:511–522.

37 37. Booth AO, Lim K, Capper H, et al. Iron status and dietary iron intake of female blood donors. Transfusion 2014; 54(3):770–774.

38 38. Sayers M, Centilli J. Concerning iron balance in blood donors. Transfusion 2014; 54(11):3010–3013.

39 39. Gorlin J. Iron man pentathlon or “we have met the enemy and they is us!” Transfusion 2014; 54(3):747–749.

40 40. Armitage J. Giving the donor his (or her) due. Transfusion 2014; 54(3):750–752.

41 41. Vassallo RR, Bravo MD, Kamel H. Ferritin testing to characterize and address iron deficiency in young donors. Transfusion 2018; 58:2861–2867.

42 42. Kiss JE, Vassallo RR. How do we manage iron deficiency after blood donation? Br J Haematol 2018; 181:590–603.

43 43. Verdon F, Burnand B, Stubi CL, et al. Iron supplementation for unexplained fatigue in non‐anemic women: double blind randomized placebo controlled trial. BMJ 2003; 326:1124–1126.

44 44. Krayenbuehl PA, Battegay E, Breymann C, et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011; 118:3222–3227.

45 45. Bialkowski W, Bryant BJ, Schlumpf KS, et al. The strategies to reduce iron deficiency in blood donors randomized trial: design, enrolment and early retention. Vox Sang 2015; 108:178–185.

46 46. United States Industry Consensus Standard for the Uniform Labeling of Blood and Blood Components Using ISBT 128. Version 3.0.0, March 2013, Tracking Number ICCBBA IG‐002. San Bernardino, CA: ICCBBA.

47 47. Eder AF, Kennedy JM, Dy BA, et al. Limiting and detecting bacterial contamination of apheresis platelets: inlet‐line diversion and increased culture volume improve component safety. Transfusion 2009; 49:1554–1563.

48 48. Satake M, Mitani T, Oikawa S, et al. Frequency of bacterial contamination of platelet concentrates before and after introduction of diversion method in Japan. Transfusion 2009; 49:2152–2157.

49 49. Ramirez‐Arcos S, Goldman M. Skin disinfection methods: prospective evaluation and postimplementation results. Transfusion 2010; 50:59–64.

50 50. McDonald C, McGuane S, Thomas J, et al. A novel rapid and effective donor arm disinfection method. Transfusion 2010; 50:53–58.

51 51. Reiss RF, Katz AJ. Platelets and factor VIII as functions of blood collection time. Transfusion 1976; 16:229–231.

52 52. Logic JR, Johnson SA, Smith JJ. Cardiovascular and hematologic responses to phlebotomy in blood donors. Transfusion 1963; 3:83–93.

53 53. Menke J, Stocker H, Sibrowski W. Cerebral oxygenation and hemodynamic during blood donation studied by near‐infrared spectroscopy. Transfusion 2004; 44:414.

54 54. Kamel H, Tomasulo P, Bravo M, et al. Delayed adverse reactions to blood donation. Transfusion 2010; 50:556–565.

55 55. Tomasulo PA, Anderson AJ, Paluso MB, et al. A study of criteria for blood donor deferral. Transfusion 1980; 20:511–518.

56 56. Goldman M, Osmond L, Yi Q‐L, et al. Frequency and risk factors for donor reactions in an anonymous blood donor survey. Transfusion 2012; 53:1979–1984.

57 57. Popovsky MA, Whitaker B, Arnold NL. Severe outcomes of allogeneic and autologous blood donation: frequency and characterization. Transfusion 1995; 35:734–737.